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ABSTRACT 
Increasing evidence suggests that fibroblast growth factors (FGFs) are neurotrophic in 
gonadotropin-releasing hormone (GnRH) neurons.   However, the extent to which FGFs are 
involved in establishing a functional GnRH system in the whole organism has not been 
investigated.  In this study, transgenic mice with the expression of a dominant-negative FGF 
receptor mutant (FGFRm) targeted to GnRH neurons were generated to examine the 
consequence of disrupted FGF signaling on the formation of the GnRH system.  To first test the 
effectiveness of this strategy, GT1 cells, a GnRH neuronal cell line, were stably transfected with 
FGFRm.  The transfected cells showed attenuated neurite outgrowth, diminished FGF-2 
responsiveness in a cell survival assay, and blunted activation of the signaling pathway in 
response to FGF-2.  Transgenic mice expressing FGFRm in a GnRH neuron-specific manner 
exhibited a 30% reduction in GnRH neuron number, but the anatomical distribution of GnRH 
neurons was unaltered.  Although these mice were initially fertile, they displayed several 
reproductive defects, including delayed puberty, reduced litter size, and early reproductive 
senescence.  Overall, our results are the first to show, at the level of the organism, that FGFs are 
one of the important components involved in the formation and maintenance of the GnRH 
system.
 2 
INTRODUCTION
Neurons that synthesize and release gonadotropin-releasing hormone (GnRH) are central 
to the initiation and maintenance of reproductive function in vertebrates.  Unlike most neurons in 
the brain, GnRH neurons do not originate within the central nervous system (CNS).  In mammals 
(1, 2), GnRH neurons first become detectable in the olfactory placode region and are thought to 
originate from this structure; recent work in zebrafish (3) suggests alternative extra-CNS origins 
for these cells that have yet to be explored in other species.  Regardless of their initial origin, 
after fate specification, GnRH neurons leave their birthplace and subsequently migrate across the 
cribriform plate to enter the forebrain.  Once migration ceases, GnRH neurons target their axons 
to the external zone of the median eminence (ME) for hormone release (4).  Regulation of GnRH 
neurons at the levels of initial birth and survival, subsequent migration and ultimate axon 
targeting is crucial, and disruption of any of these developmental phases may result in severe 
reproductive impairment.  
As a first step toward the understanding of how the GnRH system forms, we need to gain 
insights into key regulatory factors that drive the development and promote the survival of 
GnRH neurons.  Neurotrophic factors have traditionally been implicated in orchestrating a 
substantial share of these events in the central and peripheral nervous systems (5).  As much as 
neurotrophic factor research has flourished in the recent years, surprisingly little is known 
concerning the roles these multi-potent signaling molecules play in the formation and 
maintenance of the GnRH neuronal network.  Studying how GnRH neuron development is 
regulated by neurotrophic factors is critical in gaining further knowledge with regard to the types 
of signals required to trigger changes in GnRH neuronal physiology.
Fibroblast growth factors (FGFs) are signaling molecules known to have profound 
neurotrophic effects on the developing nervous system (6). Previously, we reported FGF-2, a 
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prototypic member of the FGF family, was highly neurotrophic in the immortalized GnRH 
neuronal cell lines, GT1 cells (7).  Recent studies on endogenous GnRH neurons revealed a 
subpopulation of GnRH neurons expressed FGF receptors (FGFRs; 8).  Further, the addition of 
FGF-2 stimulated neurite outgrowth and the blockade of FGF signaling inhibited fate 
specification of primary GnRH neurons in culture (8).  The clinical relevance of these in vitro
data was further strengthened by two recent reports indicating a causal relationship between the 
loss of function mutation in FGF receptor 1 (FGFR1) and Kallmann Syndrome, a pathology 
characterized by the complete or partial loss of GnRH function and anosmia (9, 10).  These 
results prompted the hypothesis that FGF signaling is critical for the proper formation and 
maintenance of a functional GnRH system. 
To test this hypothesis, we investigated if the disruption of FGFR function in GnRH 
neurons resulted in the abnormal formation of the GnRH system.  We first tested if the 
overexpression of a dominant negative FGFR mutant (FGFRm; 11, 12) in GT1 cells, a GnRH 
neuronal cell line (13), was effective in abolishing FGF responsiveness and altering the 
differentiative properties of these cells.  Next, we generated transgenic mice in which the 
expression of the FGFRm was targeted to GnRH neurons to disrupt FGFR function in a cell-
specific manner.  We determined if GnRH neuron-specific disruption of FGFR function in these 
mice led to an aberrantly formed GnRH system and/or altered fertility. Together, these results 
enable us to determine if FGF signaling is critical, at the organismal level, for the establishment 
of a neuroendocrine system essential for vertebrate reproduction. 
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RESULTS
cDNA constructs
 The components of the FGFRm cDNA, a truncated FGFR1, are illustrated in Fig. 1A.
This cDNA was used to generate CMV-FGFRm (Fig. 1B) for the transfection of the GT1 cells, 
and G-FGFRm (Fig. 1C) for the generation of transgenic mice.  Details of plasmid construction 
are described in the Materials and Methods. 
Transfected GT1-7 cells
GT1-7 cells were stably transfected with CMV-FGFRm (see Fig. 1B) to disrupt the 
function of endogenous FGFRs.  Northern blot analysis using a randomly-primed 32P-labeled
FGFR1 probe revealed that all GT1 cells expressed high levels of the endogenous FGFR1 
transcript (4.3 kb; Fig. 2).  The three GT1 clones (CMV-FGFRm-1, 2, 3) transfected with CMV-
FGFRm also expressed high levels of a smaller transcript (1.5 kb) corresponding to the truncated 
FGFRm.  One clone, CMV-FGFRm-2, expressed a smaller splice variant of the endogenous 
FGFR1 (Fig. 2).  Since one of the clones (CMV-FGFRm-3) appeared to express the highest 
FGFRm to endogenous FGFR1 ratio, this clone was expanded and used for all subsequent 
biological studies. 
CMV-FGFRm-3 cells exhibited very different cellular morphology compared to the 
CMV-null control cells (Figs. 3A, B).  CMV-null cells were elongated and extended neurites 
toward neighboring cells (Fig. 3A).  In contrast, neurite outgrowth was markedly attenuated in 
CMV-FGFR-3 cells, which appeared flattened and possessed few cellular processes (Fig. 3B).  
When CMV-null cells were cultured under a serum-deprived condition, FGF-2 at concentrations 
ranging from 0.1-1 ng/ml significantly enhanced cell survival.  However, FGF-2 treatment had 
no effect on the survival of CMV-FGFRm-3 cells (Fig. 3C). 
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 The disruption of downstream signaling pathway by FGFRm expression was investigated 
using an in-gel ERK assay (Fig. 4).  This assay estimated the ERK activity by measuring the 
ability of both p42 and p44 ERKs to phosphorylate a substrate, myelin basic protein, embedded 
within the gel.  CMV-null cells responded to the addition of 1 ng/ml FGF-2 with a robust 
activation of both p42 and p44 ERKs.  However, this activation was completely absent in CMV-
FGFRm-3 cells (Fig. 4). 
Analysis of transgene expression in the G-FGFRm mice
Two founder mice (Founders 1 and 5) with the transgene incorporated into the genome were 
generated by the pronuclear injection of G-FGFRm (see Fig. 1C) into one-cell embryos.  Both 
the G-FGFRm-1 and G-FGFRm-5 lines were initially fertile and were bred to homozygosity.  To 
verify the transgene was expressed correctly, northern blot analysis was conducted on total RNA 
isolated from the forebrain, hindbrain, and the liver (a negative control; 14) of wild-type (WT) 
and G-FGFRm mice.  Two endogenous FGFR1 transcripts, approximately 4.3 kb and 1.8 kb, 
were observed in RNA extracted from the hindbrain and forebrain of WT mice (Fig. 5A).  No 
FGFR1 transcripts were seen in the liver, a negative control (Fig. 5A).  In G-FGFRm-1 mice, in 
addition to the two endogenous FGFR1 transcripts (4.3 and 1.8 kb), a smaller FGFR1 transcript 
of approximately 1.5 kb was present only in the forebrain, where GnRH neurons reside (Fig. 
5A).  This transcript corresponds to the size of the FGFRm observed in the transfected GT1 cells 
(Fig. 2).  The hindbrain RNA was devoid of the FGFRm transcript, consistent with targeting of 
the transgene to GnRH neurons.  Again, the liver did not express any FGFR1 transcript (Fig. 
5A).
For G-FGFRm-5 animals, WT mice also expressed the 4.3 and 1.8 kb transcripts of 
endogenous FGFR1 (Fig. 5B).  However, G-FGFRm-5 mice expressed two FGFRm transcripts, 
one approximately 1.5 kb, and one 1 kb.  The latter is likely a splice variant of the former.  Both 
FGFRm transcripts were expressed in the forebrain and hindbrain, demonstrating a rather 
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promiscuous expression pattern that was not tissue-specific.  Neither WT nor G-FGFRm-5 mice 
expressed FGFRm in the liver (Fig. 5B).  Since G-FGFRm-1 mice expressed the single correct 
FGFRm transcript, and its expression was restricted to the forebrain, subsequent expression and 
phenotypic analyses were conducted exclusively with these mice. 
The targeting of the transgene to GnRH neurons within the forebrain was verified by in situ
hybridization.  Nine pairs of adjacent sections through the preoptic area (POA) were used for the 
evaluation of each animal.  One section from each pair was hybridized with a probe for GnRH, and one 
with a probe for the transgene mRNA.  The transgene was expressed in approximately 79% of GnRH 
neurons examined (33 out of a total of 42 GnRH neurons found in 9 sections; Figs. 6A, C) in G-
FGFRm-1 mice.  In sections from WT mice, 37 GnRH neurons were identified, and none was positive 
for the transgene (Figs. 6B, D).  There was no visible difference in the distribution of GnRH neurons in 
brain sections between WT and G-FGFRm-1 mice.  Labeled GnRH neurons were only observed in 
regions previously described to contain GnRH neurons.  There was no ectopic expression of the 
transgene in other brain regions including the caudate nucleus, cerebellum, cerebral cortex, 
hippocampus and thalamus in the G-FGFRm-1 mice (data not shown).  Control sense probes did not 
yield signals above background (data not shown).  These findings showed that the transgene 
expression was specifically targeted to the majority of endogenous GnRH neurons in the G-FGFRm-1
mice.  
Analysis of GnRH neurons in G-FGFRm-1 mice
To investigate if the targeted expression of FGFRm in GnRH neurons disrupted the 
formation and/or maintenance of the GnRH system, GnRH immunocytochemistry (ICC) was 
performed to examine the number and distribution of GnRH neurons in transgenic and WT mice.   
A GnRH neuronal count revealed a significant reduction  (P < 0.001) in the GnRH neuron 
number in G-FGFRm-1 mice compared to their age-matched controls (Fig. 7).  To see if this 
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phenotype was expressed predominantly in one sex over the other, the group was broken down 
into males and females. WT males and females possessed 700-800 neurons, a number consistent 
with the range of GnRH neuron number previously reported for mice (2).  A decrease in GnRH 
neuron number was observed in both male and female G-FGFRm-1 mice compared to WT 
controls, although this difference was more pronounced in the males (P < 0.001 in males, P < 
0.05 in females, Fig. 7).  Representative photomicrographs showed that the difference between 
G-FGFRm-1 and WT male mice was visible at the level of the organum vasculosum of the 
lamina terminalis (OVLT; Figs. 8A, B).  Visually, there was also a small but noticeable decline 
in GnRH fiber density in the ME of the G-FGFRm-1 males (Figs. 8C, D).  Female G-FGFRm-1
mice showed a visible but less pronounced difference in the number of GnRH neurons in the 
region of the OVLT (Figs. 8E, F).  Similar to males, G-FGFRm-1 females exhibited a modest but 
visually noticeable reduction in the fiber density targeting to the ME compared to WT mice 
(Figs. 8G, H).
To examine if the loss of GnRH neurons was brain region-specific, the distribution of 
GnRH neurons in WT and G-FGFRm-1 mice was analyzed in defined areas.  The distribution of 
GnRH neurons was not significantly different between the G-FGFRm-1 and WT male mice (Fig. 
9).  Both showed a typical pattern of GnRH neuron distribution, with fewer GnRH neurons 
anterior to the OVLT, an abrupt increase near the OVLT, and a gradual decrease posterior to 
OVLT (Fig. 9).  The distribution patterns of GnRH neurons in female WT and G-FGFRm-1 mice 
were similar to males (data not shown). 
Reproductive phenotype of G-FGFRm-1 mice
The observation that transgenic mice possessed fewer GnRH neurons suggest their fertility may 
be disrupted.  To verify this, several reproductive parameters were examined in male and female 
WT and G-FGFRm-1 mice (Table 1).  In adult females, fertility (number of days required to 
produce one litter) and the duration of estrous cycle were not significantly different between the 
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WT and transgenic mice (Table 1).  However, the size of the first litter was significantly reduced 
in G-FGFRm-1 females, although this reduction was not apparent in the subsequent litters (data 
not shown).  The age of the final litter production was also significantly younger in G-FGFRm-1
adult females (Table 1).  In the 30-day-old peripubertal animals, vaginal opening was observed 
in 100% WT females but none of the G-FGFRm-1 females, indicating delayed puberty in the 
latter group (Table 1).  A trend towards reduced hypothalamic GnRH concentration was 
observed in these females, although this was not significant (Table 1).  Peripubertal G-FGFRm-1
males had significantly reduced gonadosomatic index (GSI; [g testes mass/g body mass] x 100) 
and hypothalamic GnRH concentrations compared to WT males (Table 1).  In the peripubertal 
animals, serum LH levels did not differ significantly between WT and transgenic animals for 
either males or females (Table 1).
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DISCUSSION   
Although a growing body of evidence suggests FGF signaling is involved in the 
neurotrophic regulation of GnRH neurons (7, 8, 15), much of the focus was on the action of FGF 
at the cellular level using in vitro models.  The overall consequence of disrupting FGF signaling 
in GnRH neurons has not been investigated at the level of the organism.  In the current study, we 
employed a strategy in which the expression of FGFRm, verified to disrupt signaling in GnRH 
cell lines, was genetically targeted to GnRH neurons. Targeted expression of the FGFRm to 
GnRH neurons resulted in a 30% reduction in the GnRH neuronal population and adversely 
affected several reproductive parameters.  These results provided evidence that FGF signaling is 
critical for the maintenance of the full GnRH neuronal population into adulthood and 
consequently, the maintenance of optimal reproductive performance throughout the reproductive 
life span. 
The FGFRm is a truncated murine FGFR1 lacking the intracellular tyrosine kinase 
domain (16).  Upon ligand binding to the receptor, the truncated receptor forms nonfunctional 
heterodimers with the WT FGFRs 1, 2, and 3, thereby blocking the subsequent signaling 
pathway.  The same FGFRm targeted by the keratin and surfactant C protein promoters was
shown to disrupt FGFR functions in mouse skin and lung bud epithelia, respectively (16, 17).
The expression of the FGFRm in GT1 cells abolished the ability of transfected cells to extend 
neurites and respond to FGF-2 with enhanced survival, both well-documented neurotrophic 
effects of FGFs (6).  The diminished neurite outgrowth in FGFRm-stably transfected GT1 cells 
was likely due to the blunted autocrine response to the endogenous FGF-2 produced at low levels 
in GT1 cells (7).  The loss of neuronal morphology in FGFRm-transfected cells also suggests 
basal levels of FGF signaling may be required for the maintenance of a neuronal phenotype.  
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Lastly, the results from in-gel ERK assay support the well-documented mechanism by which 
FGFRm abolishes signaling pathways downstream of FGFR activation (11).  
It is presently unclear if CMV-FGFRm cells secreted altered levels of GnRH in culture. 
Voigt et al. (15) reported that FGF-2 did not significantly affect GnRH secretion in GT1 cells, 
suggesting FGF-2 was not involved in the acute regulation of hormone release.  Interestingly, the 
same study also reported increased mRNA levels of prohormone convertase 2, a key enzyme 
required for the initial processing of the GnRH prohormone, in GT1 cells treated with FGF-2 
(15).  The latter raised the possibility that GnRH neurons, under the long-term disruption of FGF 
signaling, may process the GnRH prohormone differently, leading to an altered levels of mature 
peptide release. 
 Northern blot analysis of tissue RNA from WT and G-FGFRm mice demonstrated the 
presence of two endogenous FGFR1 transcripts in all animals.  The 4.3 kb transcript was widely 
documented and represented the membrane spanning IIIc variant of FGFR1 (18, 19).  The 1.8 kb 
transcript may represent the IIIa variant of the secreted FGFR1 (14).  This FGFR1 was found in 
the brain (14) and may have cross-hybridized with our probe. G-FGFRm-1 animals also 
expressed a single FGFRm transcript consistent with the expected size of the transgene in the 
brain, where GnRH neurons reside.  Further examination with in situ hybridization verified that 
the transgene was indeed expressed exclusively in GnRH neurons of G-FGFRm-1 mice.  In 
contrast to this expected expression pattern, G-FGFRm-5 animals expressed an additional splice 
variant of the FGFRm (1.0 kb) and expressed the transgene ectopically in the hindbrain.  It is 
worth mentioning that our initial observations showed that G-FGFRm-5 animals had a similar 
reduction in the number of GnRH neurons (data not shown).  However, it was impossible to 
determine if the reduction in GnRH neurons was specific to the expression of the transgene in 
GnRH neurons or the consequence of the ectopic expression of the transgene.  
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G-FGFRm-1 mice exhibited an average of 30% reduction in the size of GnRH neuronal 
population, with the reduction being more prominent in males than females.  Interestingly, we 
found that WT females had significantly fewer GnRH neurons (Fig. 7; P < 0.05 by Student's t-
test) than males.  This particular sexual dimorphism has been reported in mice (20) and may 
have contributed to the sex difference in GnRH neuron reduction observed here.  These results 
were also consistent with our observation that the reduction in hypothalamic GnRH 
concentrations was more pronounced in transgenic males than females (see Table 1).  Although a 
modest reduction in GnRH fiber density was also observed in the ME of the G-FGFRm-1 mice, 
the ability of GnRH axons to target the ME did not appear grossly altered, as a large number of 
axons still reached the ME.  We believe the reduced fiber density was primarily due to the 
reduction in the number of GnRH neurons.  It is also possible that the disruption of FGFR 
function resulted in the diminished ability of GnRH neurons to branch axons, leading to 
decreased levels of fiber intensity.  Our previous observation that FGF-2 significantly promoted 
neurite branching in cultures of primary GnRH neurons supports this possibility (8). 
The uniform reduction in the number of GnRH neurons in all brain regions of the G-
FGFRm-1 mice suggests the size of the original GnRH neuronal population that migrated into 
the forebrain may have been reduced.  Several explanations could account for this reduction.  We 
previously showed that FGF signaling was required for the specification of GnRH neuronal fate 
in the olfactory placode (8).  In the absence of an FGF signal, the majority of GnRH neurons 
failed to emerge from their birthplace.  However, the expression of FGFRm in G-FGFRm-1 mice 
is coupled to the activation of the GnRH promoter, thus one would not expect FGFRm to be 
expressed and FGFR function disrupted until after GnRH neurons are fully specified.  A more 
plausible explanation for the reduced GnRH neuronal population is that in the absence of FGF 
signaling, a subpopulation of GnRH neurons failed to survive.  To date, few studies have 
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investigated the survival of GnRH neurons following fate specification.  The prevailing view was 
that 800 GnRH neurons were born in the olfactory placode, and all 800 GnRH neurons survived 
and developed normally to reach the forebrain.  However, an observation made by Wu et al. (21) 
revealed that the GnRH neuronal population actually reached a total of 2000 at embryonic day 
(E)12.75.  This number then declined to 1100 in postnatal animals, and to 800 in adults.  This 
observation suggested that less than 50% of the original GnRH neuronal population survived to
adulthood.  Moreover, it underscored the importance of survival-enhancing factors in 
maintaining and determining the final number of GnRH neurons.  FGF-2, a potent survival 
enhancing factor in GT1 cells (7; current study), may be critical in promoting the survival of 
GnRH neurons, especially during the developmental period when a large number of GnRH 
neurons vanished in the forebrain. 
Despite the absence of approximately 30% of GnRH neurons in the forebrain of G-
FGFRm-1 mice, these animals were initially fertile.  This observation is not surprising 
considering findings in the hypogonadal (hpg) mouse.  The hpg mice harbored a deletion in the 
GnRH gene that resulted in the inability to synthesize the mature GnRH peptide.  The successful 
transplantation of just 1-3 detectable GnRH neurons was effective in restoring their fertility (22-
24).  Thus, although reduced, the number of GnRH neurons present in G-FGFRm-1 mice was 
clearly sufficient for maintaining reproduction under laboratory conditions.  It is important to 
point out that although these animals reproduced, the level of reproductive activity was reduced 
compared to controls.  In particular, the delayed puberty, a reduction in the size of the first litter, 
and early reproductive senescence were all clear signs that the function of the GnRH system at 
the beginning and the end of the reproductive life span has been markedly compromised. 
One might question why serum LH levels in transgenic mice remained unchanged despite 
the reduced GnRH neuron number and content.  A recent study (25) reported similar 
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observations in mice harboring a mutation in carboxypeptidase E and thus could not process 
GnRH normally.   These mice had very low bioactive GnRH concentrations in the hypothalamus, 
displayed a number of reproductive defects, but had normal circulating LH.  One way these 
animals compensated for low GnRH was by increasing pituitary sensitivity to GnRH (25).
Another study on these mice reported similar reduction in thyrotropin-releasing hormone (TRH) 
due to processing defect, but again, the level of circulating thyrotropin (TSH) was normal (26).  
These results, together with ours, clearly demonstrated the ability of animals to develop 
pituitary-level compensatory mechanisms to cope with diminished levels of releasing hormones.   
Our current study provides the first evidence, at the level of the organism, that FGF 
signaling is involved in the maintenance of GnRH neurons.  The significant reduction in the 
number of GnRH neurons may reflect a decrease in the survival of GnRH neurons during 
development.  Several explanations could account for why only 30% of GnRH neurons were 
affected.  First, the extent of FGFR disruption may vary greatly among individual GnRH neurons 
depending on the ratio of FGFRm to WT FGFR expression.  It has been speculated that the 
FGFRm would have to be expressed at levels five to ten times higher than the WT receptor to 
completely inhibit signaling (11).  Due to the heterogeneous nature of the GnRH neuronal 
population (27-30), the level of GnRH gene expression is likely to vary among cells.
Consequently, the number of FGFRm expressed per cell is likely to vary since the expression of 
this transgene is driven by the GnRH gene promoter.  Furthermore, variations in the number of 
endogenous WT FGFRs among GnRH neurons could result in different FGFRm to WT FGFRs 
ratios, leading to unequal degree of disruption.  Secondly, FGFR function may be involved in the 
direct regulation of only a fraction of GnRH neurons.  In support of this notion, Gill et al. (8) has 
demonstrated the presence of FGFRs1 and 3 in only 20-60% of embryonic and adult GnRH 
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neurons.  The consequence of disrupting FGFR function would therefore be negligible for GnRH 
neurons lacking FGFRs or for those expressing functionally insignificant levels of FGFRs. 
If not all GnRH neurons require FGF signaling to mature, there must be other regulatory 
factors capable of supporting the GnRH system.  We hypothesize that his redundancy, 
commonly observed in the developing CNS, is critically important in safeguarding the GnRH 
system under a disrupted environment.  Neurotrophic factors such as insulin-like growth factor 
(IGF) I (31-36), IGF II (31, 37), and brain-derived neurotrophic factor (38) have all been shown 
to regulate GnRH neuronal function and may protect the GnRH system from complete 
obliteration when FGF signaling is disrupted.  Interestingly, IGF-I has also been shown to act 
synergistically with FGF-2 to regulate the function of GT1 cells (35), suggesting the 
collaborative nature of neurotrophic factor actions.  The strong evolutionary need for an 
excessively robust GnRH system for the successful propagation of species underscores the 
importance of this redundancy.   Species with a GnRH system that could be rendered 
nonfunctional as the result of a single regulatory anomaly will not survive the test of time.  Even 
under this type of redundancy, our results have unequivocally demonstrated that FGF signaling is 
one of the important components involved in the formation of a neuroendocrine system critical 
for vertebrate reproduction. 
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MATERIALS AND METHODS 
Animals
Control and transgenic mice were derived from the mating of C57BL/6J and DBA/2J 
mice, and their offspring.   All mice were housed in the animal facility under a 12L:12D cycle 
and fed water and rodent chow ad libitum.  All animal procedures complied with protocols 
approved by the Institutional Animal Care and Use Committee of the University of California at 
San Francisco and University of Colorado at Boulder. 
Construction of plasmids
The details of the FGFRm cDNA were described previously (16).  Briefly, a 1.1 kb 
FGFRm, a truncated dominant negative murine FGFR1 cDNA (exon IIIc variant) lacking the 
intracellular tyrosine kinase domain, was ligated downstream of 0.65 kb rabbit β-globin intron 
(39).  The 0.63 kb human growth hormone gene (hGH) polyadenylation (poly A) sequence was 
inserted at the 3' end of the FGFRm cDNA.  The FGFRm expression construct (Fig. 1A) was 
cloned into the pBluescript KS+ vector (Strategene, La Jolla, CA).   
 For the stable transfection of GT1 cells, a partial FGFRm construct, containing only the 
β-globin intron and FGFRm, was excised with Xba I and Bgl II, blunted with Klenow, and 
ligated into the pRc/CMV expression vector (Invitrogen, Carlsbad, CA).  The resulting plasmid 
(CMV-FGFRm) was linearized for transfections by digestion with Bgl II (Fig. 1B).
For construction of a FGFRm transgene that would target GnRH neurons, a 2.3 kb 
fragment of the rat GnRH promoter/enhancer region (G) was inserted via an Xba I site upstream 
of the rabbit β-globin intron of the FGFRm expression construct.  The GnRH promoter/enhancer 
region consists of a fragment from –2987 to –1172 appended to –441 to +104 and contains a 731 
bp deletion (13).  This GnRH promoter/enhancer fragment was used successfully to target the 
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expression of SV40 T antigen to mouse GnRH neurons for the generation of GT1 cells (13).  For 
the production of transgenic mice, the resulting plasmid was excised with Kpn I and Sal I to 
generate a transgenic fragment (G-FGFRm; Fig. 1C) for the pronuclear injection of one-cell 
embryos.   
GT1 cells and transfection
 GT1-7 cells (passages 10-23) were maintained in a GT1 medium consisting of the 
Dulbecco's Modified Eagle's Medium H21 (DMEM:H21; University of California at San 
Francisco Cell Culture Facility) supplemented with 5% fetal calf serum, 5% horse serum 
(HyClone, Logan, UT), and penicillin/streptomycin.  GT1-7 cells were transfected with 
linearized CMV-FGFRm or empty vector (CMV-Null) using DOTAP liposomal transfection 
reagent according to the manufacturer's instructions (Roche, Indianapolis, IN).  Stably 
transfected cells were selected by culturing cells in GT1 medium containing 450 µg/ml G418 
(InVitrogen).  After one month, single GT1 colonies were isolated from the culture dish with a 
sterile pipette tip and transferred to a 12-well plate.  One clone was selected for cells transfected 
with the CMV-Null vector and three clones for the CMV-FGFRm.  
Cell survival assay
 The responsiveness of transfected cells to FGF-2 was examined using a cell survival 
assay described previously (7).  Briefly, transfected cells were serum-starved for 4 days in the 
absence or presence of various doses of recombinant human FGF-2 (Promega, Madison, WI).  
Cells were trypsinized on Day 0 (before serum starvation) and Day 4, and counted with a 
hemocytometer.  Percent cell survival was calculated by dividing the cell number at Day 4 by the 
cell number at Day 0. 
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In-gel extracellular-regulated kinase (ERK) assay
 The ability of FGFRm to disrupt endogenous FGFR function, and thus downstream 
signaling events, was monitored in the transfected cells by the in-gel ERK assay described 
previously (40).  We examined the activity levels of p42 and p44 ERKs, both of which were 
robustly activated in GT1 cells by the administration of FGF-2 (7).  Details of this assay were 
described elsewhere (7). 
Generation and screening of transgenic mice
 The G-FGFRm transgene was injected into fertilized one-cell embryos as described 
previously (13).  The F2 embryos were derived from the mating of C57BL/6J and DBA/2J mice.  
Animals were screened for the presence of the transgene by polymerase chain reaction (PCR) of 
the genomic DNA isolated from tail biopsies.  For PCR, we used a 5' primer directed to the 
rabbit β-globin intron and a 3' primer directed to the FGFRm region.  Animals positive for the 
transgene were designated as G-FGFRm mice.  All G-FGFRm mice were bred to homozygosity 
by crossing heterozygous G-FGFRm mice.  Homozygosity was confirmed when a test cross 
between the G-FGFRm mouse and a nontransgenic mate generated offspring that were 100% 
transgenic.  The offspring of nontransgenic littermates produced during the heterozygote x 
heterozygote crosses were used as control WT animals to match the genetic background of G-
FGFRm mice. 
ICC and quantification of GnRH neurons
Three to 6-month-old WT and G-FGFRm mice were perfused intracardially with 20 ml 
of 0.1 M phosphate-buffered saline (PBS) followed by 30 ml of 4% paraformaldehyde in 0.1 M 
PBS.  Brains were dissected and post-fixed in 4% paraformaldehyde overnight at 4oC, and 
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cryoprotected in 20% sucrose. Forty µm floating sections were cut using a cryostat.  Sections 
were washed with 0.5% hydrogen peroxide in 0.1M PBS containing 0.4% Triton X 100 (PBST) 
for 10 minutes to the quench the endogenous peroxidase activity, rinsed 5 times with PBST, and 
incubated for 48 hours at 4oC in PBST containing an anti-GnRH antibody (LR-1, a gift of  Dr. R. 
Benoit, Montreal General Hospital; 1:10,000) and 4% normal donkey serum.  After incubation, 
sections were washed with PBST and incubated with a biotinylated donkey-anti-rabbit IgG 
(Jackson Laboratory, West Grove, PA; 1:200), washed, and incubated with the Vectastain ABC 
reagent (Vector Laboratories, Burlingame, CA) for 45 minutes.  Sections were washed and the 
immunoreactivity visualized using diaminobenzidine as the chromagen.  After the color reaction, 
sections were washed, mounted on slides, dehydrated through an ascending series (70-100%) of 
ethanol, cleared in Histoclear (National Diagnostics, Atlanta, GA), and coverslipped. 
 GnRH neurons were counted under a Nikon Eclipse E800 microscope.  Only cells with 
darkly stained cytoplasm and clear nuclei were scored.  To accurately assess the total number of 
GnRH neurons in a single animal, cells counts were made in every section ranging from the 
diagonal band of Broca through the ME. 
Northern blot analysis of transgene expression in transfected cells and mice
 Total RNA isolated from transfected GT1 cells and from tissues of the control WT and 
G-FGFRm mice were subjected to northern blot analysis to detect the expression of the FGFRm 
transgene.  Fifteen µg of total RNA was fractionated on a 1% agarose/formaldehyde gel and 
transferred onto a nylon transfer membrane (MSI, Westboro, MA) using the capillary blotting 
method.  A randomly-primed 32P-labeled cDNA probe corresponding to the exon IIIc variant of 
the murine FGFR1 was generated by the NEBlot Kit (New England Biolabs, Beverly, MA).  The 
membrane was hybridized with the FGFR1 probe at 68oC for one hour.  The membrane was then 
washed twice in 2X SSC/0.1% SDS for 15 minutes at room temperature and once in 0.1X 
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SSC/0.1% SDS for 15 minutes at 65oC.  Hybridization signals were visualized by the exposure 
of the blot to Kodak X-OMAT AR film (Eastman Kodak, Rochester, NY) or the Packard 
Cyclone phosphorimager.  The northern blot of mouse tissue RNA was stripped in 50% 
formamide/2X SSPE at 65oC and reprobed for the presence of glyceraldehyde phosphate 
dehydrogenase (GAPDH), an internal loading control, using the same procedure. 
In situ hybridization analysis of transgene expression in GnRH neurons
The specificity of the transgene expression was analyzed by in situ hybridization on adjacent 10 
µm frozen serial coronal sections from four 2-month-old homozygous G-FGFRm and four 2-
month-old WT mice.  A detailed protocol for the in situ analysis was described previously (41).
Briefly, a total of 9 pairs of adjacent sections through the POA were used for the evaluation of 
each animal.  Sections were acetylated, dehydrated progressively, and hybridized overnight at 
55oC with the probe for either GnRH or the transgene (see below) following the protocol 
suggested by the manufacturer (Roche).  To localize the mRNA for the FGFRm transgene, a 73 
bp fragment corresponding to the 5’ end of the hGH poly A fragment was used to generate a 
digoxigenin-labeled antisense riboprobe.  This region was transcribed and was contained within 
the transgene mRNA.  GnRH neurons were identified with a 345 bp digoxigenin-labeled 
antisense riboprobe to the rat GnRH cDNA (42).  The sense strand for both probes was used as a 
control.  For each pair of adjacent sections, one section was hybridized with the GnRH riboprobe 
while the adjacent section was hybridized with the transgene riboprobe.  After hybridization, the 
slides were washed under high stringency and processed directly for detection of the digoxigenin 
signal.  The sections were examined with a Leica DMR photomicroscope under bright-field 
optics.
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Monitoring the reproductive function of female and male WT and transgenic mice
Reproductive function of adult WT and G-FGFRm females were assessed by four 
criteria: the length of the estrous cycle, the mean duration required for the production of one 
litter, the size of the first litter, and the age of the female when the final litter was produced.  The 
length of the estrous cycle was assessed by vaginal smears obtained daily for two weeks on 
females between 3-4 months of age.  To assess the average duration required to produce a litter, 
the number of litters produced by females (between 3-8 months of age) in the constant presence 
of a male was recorded and normalized for the duration.  We retired the female breeders when 
they failed to produce litters for three months.  Thus, the final litter was defined as the litter 
before the breeding female was retired.  Pubertal onset was assessed by measuring the incidence 
of vaginal opening in 30-day-old females, and GSI in 30-day-old males. 
Hormone measurements
Hypothalamic GnRH concentrations in WT and G-FGFRm males was measured by a 
GnRH radioimmunoassay (43).  Serum luteinizing hormone (LH) was measured by a sensitive 
sandwich immunoassay described previously (44).
Statistical  analysis
Differences among multiple groups were analyzed by the one-way analysis of variance 
(ANOVA) followed by the Tukey's post-hoc test.  Difference between two groups was analyzed 
by the Student's t-test.  Difference in percent animals with vaginal opening between WT and 
transgenic animals was analyzed by the Fisher's exact test.  Differences were considered 
significant when P < 0.05. 
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TABLE 1.  Reproductive parameters of WT and G-FGFRm-1 female and male mice.  
          Females (n = 4-8)           Males (n = 4-6) 
        WT G-FGFRm-1   Control G-FGFRm-1
Fertility (days/litter)  28.3 + 3.3   25.4 + 1.3          --           -- 
Length of estrous cycle  (days)    5.6 + 1.4    4.8 + 0.6          --           -- 
Number of pups in the first litter     8.1 + 0.6    6.4 + 0.4*          --           -- 
Age of last litter production (days)    392 + 14   289 + 38*          --           -- 
Percent vaginal opening at 30 days (%)   100 (8/8)      0 (0/8)*          --           -- 
GSI at 30 days (%)          --           --  0.64 + 0.02 0.51 + 0.02* 
30-day-old hypothalamic GnRH (pg/µg protein)   1.4 + 0.3   0.8 + 0.1    1.3 + 0.2   0.5 + 0.1* 
30-day-old plasma LH (ng/ml)  0.15 + 0.01   0.15 + 0.01   0.19 + 0.03  0.28 + 0.07 
All values were expressed as mean + SEM.   
* P < 0.05 compared to the controls of the same sex. 
ND = not detectable.  Parameters not measured or not applicable are denoted by --. 
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LEGENDS 
FIG. 1. Schematic diagrams of (A) the FGFRm expression construct, (B) the CMV-FGFRm 
plasmid used for the transfection of the GT1-7 cells, and (C) the G-FGFRm fragment used to 
generate the G-FGFRm mice.   For (A), ATG denotes the translation initiation site; AB denotes 
the acid box domain; Ig-II and Ig-IIIc denote the second immunoglobulin-like (Ig) domain and 
the exon IIIc variant of the third Ig domain; TM denotes the transmembrane domain; double 
vertical lines denote translation stop codons in all three frames.  For (B), black boxes indicate the 
original components of the pRc/CMV expression vector.  The expression of FGFRm in this 
construct is driven by the cytomegalovirus (CMV) promoter.  FGFRm is flanked at the 3' region 
by the bovine GH (bGH) polyadenylation signal and the neomycin-resistant gene (Neo).
FIG. 2.  Northern blot analysis of endogenous FGFR1 and FGFRm transcripts in transfected 
GT1-7 cells.  CMV-null, cells transfected with the linearized pRc/CMV vector without the 
FGFRm insert; CMV-FGFRm1, 2 and 3, three clones transfected with linearized CMV-FGFRm. 
The larger transcript at 4.3 kb is the endogenous WT FGFR1.  The smaller transcript at 1.5 kb is 
FGFRm.  CMV-FGFRm-2 cells also expressed a splice variant of the wild type FGFR1. 
FIG. 3.  Morphology and FGF-induced survival of CMV-null cells and CMV-FGFRm-3 cells. 
(A) CMV-null cells were highly neuronal in morphology and possessed extensive neurites, 
whereas (B) CMV-FGFRm-3 cells were flattened and possessed very few processes. (C) FGF-2 
promoted cell survival in CMV-null cells but not in CMV-FGFRm-3 cells.  Each bar represents 
mean + SEM from quadruplicate determinations.  Dissimilar letters above the bars indicate a 
significant difference between the groups (P < 0.05). 
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 FIG. 4.  FGF-2 (1 ng/ml) activated p42 and p44 ERK activity in CMV-null cells but not in 
CMV-FGFRm-3 cells.  Activity of ERKs was visualized by the phosphorylation of myelin basic 
protein co-polymerized in the gel.  Arrows show the positions of p42 and p44 ERKs.  Rapid 
activation of both ERKs was seen 5 minutes after the addition of FGF-2 in control cells. 
FIG. 5.  Northern blot analysis of endogenous FGFR1 and FGFRm transgene expression in (A)
WT control and G-FGFRm-1 mice, and (B) WT control and G-FGFRm-5 mice.  F, forebrain; H, 
hindbrain; L, liver (negative control).  In the forebrain and hindbrain, two transcripts (4.3 kb and 
1.8 kb) representing the endogenous FGFR1 are indicated by arrowheads.  In G-FGFRm-1 mice 
(A), a single transcript (1.5 kb) representing the FGFRm was present in the forebrain (arrow) but 
absent in the hindbrain.  In G-FGFRm-5 mice (B), two transcripts (1.5 kb and 1.0 kb) 
representing the two variants of the FGFRm were present in both the forebrain and hindbrain 
(arrows).  Liver RNA samples were consistently devoid of endogenous FGFR1 and FGFRm.
GAPDH was used as a loading control. 
FIG. 6. Localization of transgene expression in GnRH neurons of G-FGFRm-1 mice by in situ
hybridization. Messenger RNA for GnRH and the transgene were labeled by specific riboprobes 
on adjacent serial sections from the POA of G-FGFRm-1 (A, C) and WT mice (B, D).  In the G-
FGFRm-1 mouse, eight GnRH neurons (A) were labeled, and six of these were also labeled for 
the transgene (C). Arrows in (A) point to GnRH neurons devoid of the transgene mRNA.  In the 
WT mouse, four GnRH neurons (B) were labeled while no labeling was observed for the 
transgene (D).  Scale bar = 40 µm. 
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FIG. 7.  Total number of GnRH neurons in the forebrain of adult WT control and G-FGFRm-1
mice.  A significant difference in GnRH neuronal number was observed between WT control and 
G-FGFRm-1 mice in males and females combined (**P < 0.001), in males only (**P < 0.001), 
and in females only (*P < 0.05).  Each bar represents mean + SEM.  N = 4 and 5 for WT control 
and G-FGFRm-1 females, respectively; n = 5 for both WT control and G-FGFRm-1 males. 
FIG. 8. Representative photomicrographs of GnRH neurons at the plane of the OVLT (A, B, E, 
F), and GnRH axon terminals in the median eminence (C, D, G, H).  (A-D) GnRH neurons and 
terminals in male WT control (A, C) and G-FGFRm-1 (B, D) mice.  (E-H) GnRH neurons and 
terminals in female WT control (E, G) and G-FGFRm-1 (F, H) mice.  Overall, GnRH neurons 
were visibly reduced in both male and female G-FGFRm-1 mice near the OVLT (compare A to 
B, E to F), but this reduction was more pronounced in males.  A very small reduction in GnRH 
fiber density in the ME was also observed in both male and female G-FGFRm-1 mice (compare 
C to D, G to H).  Scale bars = 100 µm.
FIG. 9. The distribution of forebrain GnRH neurons in (A) WT control and (B) G-FGFRm-1
male mice.  The X axis, from left to right, represents the rostral to caudal forebrain sequence in 
40 µm increments.  OVLT is used as a landmark and denoted as 0.  Negative numbers on the X 
axis indicate regions rostral to the OVLT, whereas positive numbers indicate regions caudal to 
the OVLT.  Each bar represents mean + SEM.  N = 4 for control mice, and n = 5 for G-FGFRm-
1 mice.  
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